{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:40:46Z","timestamp":1794246046514,"version":"4.9.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroImage: Clinical"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.nicl.2025.103765","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:34:30Z","timestamp":1741624470000},"page":"103765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0053-9519","authenticated-orcid":false,"given":"Leonardo","family":"Iaccarino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Tunali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Navitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupa K.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nicl.2025.103765_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamaneurol.2023.0997","article-title":"Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial","volume":"80","author":"Altomare","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","article-title":"Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease","volume":"12","author":"Amadoru","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0015","unstructured":"AMYPAD, 2022. AMYPAD deliverable 5.6: final report on basic modelling. https:\/\/amypad.eu\/wp-content\/uploads\/2022\/10\/D5.6-AMYPAD.pdf (accessed 05 April 2024)."},{"key":"10.1016\/j.nicl.2025.103765_b0020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical use and utility of amyloid imaging","volume":"58","author":"Barthel","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0025","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13550-018-0456-7","article-title":"Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods","volume":"8","author":"Battle","year":"2018","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.nicl.2025.103765_b0040","article-title":"Probabilistic estimation for across-batch compatibility enhancement for amyloid PET","volume":"15","author":"Bilgel","year":"2023","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.nicl.2025.103765_b0045","doi-asserted-by":"crossref","unstructured":"Boess, F., Lane, C., Scelsi, M., Delmar, P., Hofmann, C., Tonietto, M., Klein, G., Kerchner, G.A., Baudler, M., Doody, R. 2022. Baseline participant characteristics of GRADUATION: a study to evaluate once weekly subcutaneous administration of gantenerumab. Presented at: Alzheimer\u2019s Association International Conference (AAIC); July 31\u2013August 4, 2022; San Diego, CA, USA.","DOI":"10.1002\/alz.061781"},{"key":"10.1016\/j.nicl.2025.103765_b0050","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1002\/alz.13761","article-title":"Investigating reliable amyloid accumulation in Centiloids: results from the AMYPAD Prognostic and Natural History Study","volume":"20","author":"Bollack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/alz.074619","article-title":"A Centiloid cut-off to help predict true amyloid accumulation","volume":"19","author":"Bollack","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2022.119527","article-title":"\u03b2-amyloid PET harmonisation across longitudinal studies: application to AIBL, ADNI and OASIS3","volume":"262","author":"Bourgeat","year":"2022","journal-title":"Neuroimage"},{"key":"10.1016\/j.nicl.2025.103765_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117593","article-title":"Non-negative matrix factorisation improves centiloid robustness in longitudinal studies","volume":"226","author":"Bourgeat","year":"2021","journal-title":"Neuroimage"},{"key":"10.1016\/j.nicl.2025.103765_b0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","article-title":"Implementing the centiloid transformation for 11C-PiB and \u03b2-amyloid 18F-PET tracers using CapAIBL","volume":"183","author":"Bourgeat","year":"2018","journal-title":"Neuroimage"},{"key":"10.1016\/j.nicl.2025.103765_b0075","article-title":"A universal neocortical mask for centiloid quantification","volume":"15","author":"Bourgeat","year":"2023","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.nicl.2025.103765_b0080","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer\u2019s therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.nicl.2025.103765_b0085","first-page":"84","article-title":"Correlation between two methods of florbetapir PET quantitative analysis","volume":"7","author":"Breault","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.nicl.2025.103765_b0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-022-01048-x","article-title":"Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects\u2014a MissionAD tau sub-study","author":"Bullich","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-021-00807-6","article-title":"Early detection of amyloid load using 18F-florbetaben PET","volume":"13","author":"Bullich","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0105","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0110","doi-asserted-by":"crossref","unstructured":"Charil, A., Nelson, T., Devanarayan, V., Reilhac, A., Dhadda, S., Reyderman, L., Irizarry, M. 2023. Discordance in amyloid positivity defined by Visual Reads VR and Centiloids CL. Presented at: Alzheimer\u2019s Association International Conference (AAIC); July 16\u201320, 2023; Amsterdam, The Netherlands.","DOI":"10.1002\/alz.082823"},{"key":"10.1016\/j.nicl.2025.103765_b0115","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00259-023-06209-0","article-title":"Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a phase 2\/3 clinical trial of anti-amyloid-\u03b2 monoclonal antibodies in dominantly inherited Alzheimer\u2019s disease","volume":"50","author":"Chen","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0120","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/alz.13677","article-title":"Harmonizing florbetapir and PiB PET measurements of cortical A\u03b2 plaque burden using multiple regions-of-interest and machine learning techniques: an alternative to the Centiloid approach","volume":"20","author":"Chen","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","article-title":"Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias","author":"Ch\u00e9telat","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0135","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the Amypad consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.nicl.2025.103765_b0140","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/alz.12886","article-title":"Quantification of [18F]florbetaben amyloid-PET imaging in a mixed memory clinic population: the ABIDE project","volume":"19","author":"Collij","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0145","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-020-05174-2","article-title":"Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent","volume":"48","author":"Collij","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0155","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jalz.2019.02.005","article-title":"Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL\u00ae approaches: validation against histopathology","volume":"15","author":"Dor\u00e9","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/alz.087430","article-title":"Effect of scanner on beta amyloid quantification in a head-to-head comparison of 18F-NAV4694 Centiloid measurements between Biograph Vision, Gemini and Biograph mCT","volume":"20","author":"Dore","year":"2024","journal-title":"Alzheimers Dement.,"},{"key":"10.1016\/j.nicl.2025.103765_b0165","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00259-021-05191-9","article-title":"Relationship between amyloid and tau levels and its impact on tau spreading","volume":"48","author":"Dor\u00e9","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0170","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0175","unstructured":"European Medicines Agency, 2023. AMYPAD - Centiloid measure of amyloid PET to quantify brain amyloid burden. Summary of EMA SAWP discussion meeting. https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-cl-additional-analyses-presented-discussion-meeting-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf (accessed 05 April 2024)."},{"key":"10.1016\/j.nicl.2025.103765_b0180","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use, 2024. Qualification opinion for Centiloid measure of amyloid PET to quantify brain amyloid deposition. https:\/\/www.ema.europa.eu\/en\/documents\/other\/qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition_en.pdf (accessed 24 February 2025)."},{"issue":"2","key":"10.1016\/j.nicl.2025.103765_b0185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-171093","article-title":"A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer\u2019s disease","volume":"63","author":"Fantoni","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.nicl.2025.103765_b0190","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1212\/WNL.0000000000011214","article-title":"Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation","volume":"96","author":"Farrell","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2025.103765_b0195","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.nicl.2025.103765_b0200","unstructured":"Gillman, A., Bourgeat, P., Cox, T., Li, S., Villemagne, V., Fripp, J., O'Keefe, G., Huang, K., Krishnadas, N., Feizpour, A., Williams, R., Bozinoski, S., Rowe, C., Dore, V., 2024. Amyloid quantification is dependent on scanner: a head-to-head comparison of 18F-NAV4694 Centiloid measurements between three PET\/CT scanners. Presented at: Human Amyloid Imaging (HAI); January 17\u201319, 2024; Miami, FL, USA."},{"key":"10.1016\/j.nicl.2025.103765_b0205","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","article-title":"Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study","volume":"48","author":"Hanseeuw","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/alz.069220","article-title":"Neuropathological autopsy findings in an individual with Alzheimer\u2019s disease who received long-term treatment with lecanemab (BAN2401)","volume":"18","author":"Honig","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2021.118775","article-title":"rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data","volume":"246","author":"Iaccarino","year":"2022","journal-title":"Neuroimage"},{"key":"10.1016\/j.nicl.2025.103765_b0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40478-016-0399-z","article-title":"Post-mortem histopathology underlying \u03b2-amyloid PET imaging following flutemetamol F 18 injection","volume":"4","author":"Ikonomovic","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nicl.2025.103765_b0230","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s12149-022-01769-x","article-title":"Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer\u2019s disease","volume":"36","author":"Imabayashi","year":"2022","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0235","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0240","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0245","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2025.103765_b0250","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJMoa2310168","article-title":"Biomarker changes during 20 years preceding Alzheimer\u2019s disease","volume":"390","author":"Jia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0255","unstructured":"Johnson, K., 2023. Biomarker assessments from Clarity AD: downstream implications of targeting protofibrils and tau as a predictive biomarker. Presented at: Clinical Trials on Alzheimer\u2019s Disease (CTAD); October 24\u201327, 2023; Boston, MA, USA."},{"key":"10.1016\/j.nicl.2025.103765_b0260","doi-asserted-by":"crossref","first-page":"e2282","DOI":"10.1212\/WNL.0000000000200287","article-title":"Characterizing amyloid-positive individuals with normal tau PET levels after 5 years: an ADNI study","volume":"98","author":"Josephs","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2025.103765_b0265","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00259-023-06279-0","article-title":"Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods","volume":"50","author":"Jovalekic","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0275","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0285","unstructured":"Kulic, L., Alcaraz, F., Vogt, A., Hofmann, C., Barrington, P., Marchesi, M., Wojtowicz, J., Klein, G., Croney, R., Agnew, D., Sickert, D., Janseen, N., Abrantes, J.A., Ahlers, S., Delmar, P., Wiesel, I., Svoboda, H., 2023. The anti-amyloid beta BrainShuttleTM antibody trontinemab rapidly reduces amyloid plaques in participants with Alzheimer\u2019s disease. Presented at: Clinical Trials on Alzheimer\u2019s Disease (CTAD); October 24\u201327, 2023; Boston, MA, USA."},{"key":"10.1016\/j.nicl.2025.103765_b0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0295","doi-asserted-by":"crossref","unstructured":"La Joie, R., Mundada, N., Blazhenets, G., Mejia-Perez, J.A., Schonhaut, D., Zeltzer, E., Soleimani-Meigooni, D., Cho, H., Ranasinghe, K., Windon, C., Yadollahikhales, G., Iaccarino, L., Koeppe, R., Carrillo, M., Hanna, L., Gatsonis, C., March, A., Siegel, B.A., Hillner, B.E., Whitmer, R.A., Rabinovici, G., 2023a. Quantitative amyloid-PET in real-world practice: lessons from the Imaging Dementia\u2014Evidence for Amyloid Scanning (IDEAS) study. Presented at: Alzheimer\u2019s Association International Conference (AAIC); July 16\u201320, 2023; Amsterdam, The Netherlands.","DOI":"10.1002\/alz.082874"},{"key":"10.1016\/j.nicl.2025.103765_b0300","doi-asserted-by":"crossref","unstructured":"La Joie, R., Mundada, N., Iaccarino, L., Soleimani-Meigooni, D., Zeltzer, E., Windon, C., Tanner, J., Lawh Heath, C., Shankar, R., Amuiri, A., Cho, H., Ackley, S.F., Blazhenets, G., Aisen, P., Eloyan, A., Koeppe, R., Carrillo, M., Dickerson, B.C., Apostolova, L.G., Rabinovici, G., 2023b. Amyloid-PET, tau-PET, and their association in sporadic early-onset Alzheimer\u2019s disease: cross-sectional and longitudinal data from the LEADS study. Presented at: Alzheimer\u2019s Association International Conference; July 16\u201320, 2023; Amsterdam, The Netherlands.","DOI":"10.1002\/alz.078003"},{"key":"10.1016\/j.nicl.2025.103765_b0305","unstructured":"La Joie, R., Sexton, C., Cummings, J.L., Galasko, D., Ikonomovic, M.D., Landau, S., Llibre-Guerra, J.J., Mummery, C.J., Ossenkoppele, R., Price, J.C., Risacher, S.L., Smith, R., Van Dyck, C.H., Carrillo, M.C., 2024. \u201cTreatment Related Amyloid Clearance\u201d (TRAC): a framework to characterize a new biomarker state in the era of anti-amyloid therapies. Presented at: Human Amyloid Imaging (HAI); January 17\u201319, 2024; Miami, FL, USA."},{"key":"10.1016\/j.nicl.2025.103765_b0310","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/alz.12668","article-title":"Quantification of amyloid beta and tau PET without a structural MRI","volume":"19","author":"Landau","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0315","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","article-title":"Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study","volume":"139","author":"Leuzy","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nicl.2025.103765_b0320","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.nicl.2025.103765_b0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13195-023-01242-5","article-title":"Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults","volume":"15","author":"Luckett","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0330","article-title":"Quantitative evaluation of 18F-flutemetamol PET in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study","volume":"11","author":"Matsuda","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0335","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s12149-022-01792-y","article-title":"Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer\u2019s disease: a multicenter study","volume":"36","author":"Matsuda","year":"2022","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0340","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0345","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","article-title":"SNMMI procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0","volume":"57","author":"Minoshima","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0350","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0355","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2025.103765_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nicl.2025.103765_b0365","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0370","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/alz.12317","article-title":"AMYQ: an index to standardize quantitative amyloid load across PET tracers","volume":"17","author":"Pegueroles","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-023-00994-3","article-title":"Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment","volume":"13","author":"Pemberton","year":"2023","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.nicl.2025.103765_b0380","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: a state-of-the-art review","volume":"49","author":"Pemberton","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0385","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer\u2019s disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.nicl.2025.103765_b0390","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer\u2019s disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0395","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.nicl.2025.103765_b0400","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: design of a prevention trial for Alzheimer\u2019s disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0405","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1007\/s00259-022-05808-7","article-title":"Classification of 18F-flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth","volume":"49","author":"Reinartz","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0410","doi-asserted-by":"crossref","first-page":"218","DOI":"10.14283\/jpad.2021.4","article-title":"Amyloid and APOE status of screened subjects in the elenbecestat MissionAD phase 3 program","volume":"8","author":"Roberts","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.nicl.2025.103765_b0415","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","article-title":"18F-florbetaben PET beta-amyloid binding expressed in Centiloids","volume":"44","author":"Rowe","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.nicl.2025.103765_b0420","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2967\/jnumed.115.171595","article-title":"Standardized expression of 18F-NAV4694 and 11C-PiB \u03b2-amyloid PET results with the Centiloid scale","volume":"57","author":"Rowe","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0425","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","article-title":"Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach","volume":"13","author":"Royse","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0430","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0435","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Salvad\u00f3","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0440","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc0655","article-title":"The cortical origin and initial spread of medial temporal tauopathy in Alzheimer\u2019s disease assessed with positron emission tomography","volume":"13","author":"Sanchez","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0445","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-020-00765-5","article-title":"Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer\u2019s disease: findings from the Colombia-Boston (COLBOS) biomarker study","volume":"13","author":"Sanchez","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nicl.2025.103765_b0450","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.24125","article-title":"Mild to moderate Alzheimer dementia with insufficient neuropathological changes","volume":"75","author":"Serrano-Pozo","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.nicl.2025.103765_b0460","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes. The TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nicl.2025.103765_b0465","article-title":"Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer\u2019s disease","volume":"9","author":"Shcherbinin","year":"2023","journal-title":"Alzheimers Dement. (N. Y.)"},{"issue":"8","key":"10.1016\/j.nicl.2025.103765_b0470","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1002\/alz.13883","article-title":"Stress testing the Centiloid: precision and variability of PET quantification of amyloid pathology","volume":"20","author":"Shekari","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0475","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"TRAILBLAZER-ALZ 2 Investigators Donanemab in early symptomatic Alzheimer disease: the trailblazer-alz 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.nicl.2025.103765_b0480","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2967\/jnumed.122.264031","article-title":"The RSNA QIBA profile for amyloid PET as an imaging biomarker for cerebral amyloid quantification","volume":"64","author":"Smith","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0485","unstructured":"Sperling, R., 2023. Lecanemab for the treatment of early Alzheimer\u2019s disease: the extension of efficacy results from Clarity AD. Presented at: Clinical Trials on Alzheimer\u2019s Disease (CTAD); October 24\u201327, 2023; Boston, MA, USA."},{"key":"10.1016\/j.nicl.2025.103765_b0490","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of solanezumab in preclinical Alzheimer\u2019s disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0495","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.nicl.2018.04.022","article-title":"Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies","volume":"19","author":"Su","year":"2018","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.nicl.2025.103765_b0500","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.dadm.2018.12.008","article-title":"Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies","volume":"11","author":"Su","year":"2019","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.nicl.2025.103765_b0505","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s11307-022-01735-z","article-title":"Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer\u2019s disease","volume":"24","author":"Sur","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.nicl.2025.103765_b0510","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A\u03b2-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2025.103765_b0515","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2967\/jnumed.120.245209","article-title":"Determining amyloid-beta positivity using 18F-AZD4694 PET imaging","volume":"62","author":"Therriault","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0520","article-title":"Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET","volume":"15","author":"Therriault","year":"2023","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.nicl.2025.103765_b0525","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1212\/WNL.0000000000011222","article-title":"Association of \u03b2-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals","volume":"96","author":"van der Kall","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nicl.2025.103765_b0530","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nicl.2025.103765_b0535","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-023-02631-8","article-title":"Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab","volume":"146","author":"VandeVrede","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nicl.2025.103765_b0540","unstructured":"Wang, J., Lu, M., Iaccarino, L., Arora, A., Morris, A., Kim, M.J., Kennedy, I., Kotari, V., Burnham, S., Collins, E.C., Pontecorvo, M., 2024. Comparison of visual interpretation and quantitation in detecting amyloid pathology using florbetapir F-18 PET imaging: results from nuclear medicine physicians or radiologists practicing at community healthcare settings. Presented at: Human Amyloid Imaging (HAI); January 17\u201319; Miami, FL, USA."},{"key":"10.1016\/j.nicl.2025.103765_b0545","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/alz.13444","article-title":"Characterizing the emergence of amyloid and tau burden in Down syndrome","volume":"20","author":"Zammit","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nicl.2025.103765_b0550","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cpt.2536","article-title":"Toward bridging unmet medical need in early Alzheimer\u2019s disease: an evaluation of beta-amyloid (A\u03b2) plaque burden as a potential drug development tool","volume":"111","author":"Zhu","year":"2022","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["NeuroImage: Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221315822500035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221315822500035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:50:37Z","timestamp":1749023437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221315822500035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":110,"alternative-id":["S221315822500035X"],"URL":"https:\/\/doi.org\/10.1016\/j.nicl.2025.103765","relation":{},"ISSN":["2213-1582"],"issn-type":[{"value":"2213-1582","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research","name":"articletitle","label":"Article Title"},{"value":"NeuroImage: Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nicl.2025.103765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103765"}}